Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Recombinant PMS2 (Postmeiotic Segregation Increased 2) Antibody [PMS2/4373R]

In Stock
HuProt Validated
Catalog Number Formulation Size Price
5395-RBM1-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
5395-RBM1-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
5395-RBM1-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Flow Cytometry (Flow)
1-2ug/million cells
Immunofluorescence (IF)
1-3ug/ml
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes
Western Blot (WB)
2-4ug/ml

Summary

PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

Product Properties & Targets

Host
Rabbit
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Nucleus
Gene Name
Positive Control
HeLa or Jurkat cells. Human colon carcinoma.
Immunogen
Synthetic peptide corresponding to residues within aa1-100 of human PMS2 (exact sequence is proprietary)
Alternate Names
Mismatch repair endonuclease PMS2, DNA mismatch repair protein PMS2, PMS1 protein homolog 2, DNA mismatch repair protein PMS2; hereditary non-polyposis colorectal cancer type 4 (HNPCC4); Mismatch repair gene PMSL2; PMS1 protein homolog 2; postmeiotic segregation increased 2 (S. cerevisiae); PMS2CL

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
PMS2/4373R
Chromosome Location
7p22.2
Mol. Weight of Antigen
96kDa

Functions

  • Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages.

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant PMS2 (Postmeiotic Segregation Increased 2) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK